EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Impact of Sugammadex versus Neostigmine on Diaphragmatic Function and Respiratory Recovery in Morbidly Obese Patients with Moderate Neuromuscular Block: A Randomised Double-Blind Controlled Trial

Yu-Xin Chai, Yu-Hui Wang, Lei Wu, Lin-Xin Wang, Shu-Ran Li, Zhuang Qiu, Jing-Wen Yin, Bao-Shuang Zhang, Guang-Lei Wang iD

Drug Design, Development and Therapy · 2026-04 · Volume 20 · 1-11

DOI: 10.2147/dddt.s577208 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026-04. Verfasst von Yu-Xin Chai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Diaphragm, Neostigmine, Neuromuscular Blockade, Obesity, Morbid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly obese cohort, and the mechanism underlying its reduction of postoperative pulmonary complications remain unclear. This study aims to compare the effects of sugammadex and neostigmine on diaphragmatic function and respiratory recovery in morbidly obese patients after surgery, and to investigate the role of diaphragmatic function in the reduction of sugammadex-associated postoperative pulmonary complications. Patients and Methods: For neuromuscular blockade reversal, 104 morbidly obese patients with moderate neuromuscular block (train-of-four count = 2, ratio < 0.9) were randomly assigned to receive either neostigmine (50 μg kg-1+atropine 20 μg kg-1, n=51) or sugammadex (2 mg kg-1, n=53). Measurements of diaphragmatic excursion (DE) and thickening fraction (TF) were taken during deep and quiet breathing at T0 (baseline), T1 (10 min), and T2 (30 min) after extubation. The primary outcome measure was the change in deep breathing diaphragmatic excursion (ΔDE DB ) from baseline at T2. The secondary outcome measures included ΔDE QB , ΔDE DB , and ΔTF at T1; ΔDE QB and ΔTF at T2; postoperative oxygenation index; number of respiratory reminders; and the frequency of postoperative pulmonary complications.

Results

At T2, the ΔDE DB was smaller in the sugammadex group compared with the neostigmine group (0.05 cm vs. 0.28 cm; P < 0.001). At T1, the ΔDE QB , ΔDE DB , and ΔTF all differed significantly between groups, as did the ΔTF at T2 (all P ≤ 0.001). The sugammadex group also demonstrated a higher oxygenation index ( P =0.004) and a lower incidence of postoperative pulmonary complications ( P =0.007).

Conclusion

In morbid obesity, sugammadex promotes faster diaphragmatic recovery and improves respiratory outcomes compared with neostigmine and is associated with a lower incidence of postoperative pulmonary complications. Keywords: diaphragm, obesity, morbid, sugammadex, postoperative pulmonary complications

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiaphragmNeostigmineNeuromuscular BlockadeObesity, MorbidSugammadexAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodPostoperative Complications

Stichwörter der Autor:innen

diaphragmmorbidobesitypostoperative pulmonary complicationssugammadex

Substanzen

NeostigmineSugammadex

Autor:innen und Institutionen

  • Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
  • Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
  • Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

ORCID-Profile: Guang-Lei Wang

Zitieren

APA

Chai, Y. X., Wang, Y. H., Wu, L., Wang, L. X., Li, S. R., Qiu, Z., Yin, J. W., Zhang, B. S., & Wang, G. L. (2026). Impact of Sugammadex versus Neostigmine on Diaphragmatic Function and Respiratory Recovery in Morbidly Obese Patients with Moderate Neuromuscular Block: A Randomised Double-Blind Controlled Trial. Drug Design, Development and Therapy, Volume 20, 1-11. https://doi.org/10.2147/dddt.s577208

Vancouver

Chai YX, Wang YH, Wu L, Wang LX, Li SR, Qiu Z, et al. Impact of Sugammadex versus Neostigmine on Diaphragmatic Function and Respiratory Recovery in Morbidly Obese Patients with Moderate Neuromuscular Block: A Randomised Double-Blind Controlled Trial. Drug Design, Development and Therapy. 2026;Volume 20:1-11. doi:10.2147/dddt.s577208

BibTeX
@article{Chai2026,
  author = {Chai, Yu-Xin and Wang, Yu-Hui and Wu, Lei and Wang, Lin-Xin and Li, Shu-Ran and Qiu, Zhuang and Yin, Jing-Wen and Zhang, Bao-Shuang and Wang, Guang-Lei},
  title = {Impact of Sugammadex versus Neostigmine on Diaphragmatic Function and Respiratory Recovery in Morbidly Obese Patients with Moderate Neuromuscular Block: A Randomised Double-Blind Controlled Trial},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/dddt.s577208}
}
Kostenlos starten →